These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 16137672)

  • 1. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
    Grönholm T; Cheng ZJ; Palojoki E; Eriksson A; Bäcklund T; Vuolteenaho O; Finckenberg P; Laine M; Mervaala E; Tikkanen I
    Eur J Pharmacol; 2005 Sep; 519(3):267-76. PubMed ID: 16137672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats.
    Cheng ZJ; Grönholm T; Louhelainen M; Finckenberg P; Merasto S; Tikkanen I; Mervaala E
    J Hypertens; 2005 Sep; 23(9):1757-70. PubMed ID: 16093923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat.
    Loch D; Hoey A; Brown L
    Clin Exp Hypertens; 2006 Jul; 28(5):475-88. PubMed ID: 16820344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction.
    Bäcklund T; Palojoki E; Saraste A; Grönholm T; Eriksson A; Lakkisto P; Vuolteenaho O; Nieminen MS; Voipio-Pulkki LM; Laine M; Tikkanen I
    Cardiovasc Res; 2003 Mar; 57(3):727-37. PubMed ID: 12618234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
    Emoto N; Raharjo SB; Isaka D; Masuda S; Adiarto S; Jeng AY; Yokoyama M
    Hypertension; 2005 Jun; 45(6):1145-52. PubMed ID: 15897363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial and adverse renal and vascular effects of the vasopeptidase inhibitor omapatrilat in renovascular hypertensive rats.
    Wenzel UO; Wolf G; Jacob I; Schwegler C; Qasqas A; Amann K; Helmchen U; Stahl RA
    Nephrol Dial Transplant; 2003 Oct; 18(10):2005-13. PubMed ID: 13679474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
    Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
    Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet.
    Gröholm T; Finckenberg P; Palojoki E; Saraste A; Bäcklund T; Eriksson A; Laine M; Mervaala E; Tikkanen I
    Hypertens Res; 2004 Aug; 27(8):609-18. PubMed ID: 15492481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat.
    Lapointe N; Blais C; Adam A; Parker T; Sirois MG; Gosselin H; Clément R; Rouleau JL
    J Am Coll Cardiol; 2002 May; 39(10):1692-8. PubMed ID: 12020499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction.
    Blais C; Lapointe N; Rouleau JL; Clément R; Gervais N; Geadah D; Adam A
    Peptides; 2001 Jun; 22(6):953-62. PubMed ID: 11390026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the vasopeptidase inhibitor omapatrilat on peri- and postmyocardial infarction in Zucker lean rats.
    Lapointe N; Parker TG; Tsoporis JN; Nguyen QT; Marcotte F; Adam A; Lou I; Rouleau JL
    Can J Cardiol; 2005 Mar; 21(3):291-7. PubMed ID: 15776120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic and renal effect of chronic omapatrilat in sodium-restricted, one-kidney, one-clip hypertensive rats.
    Jover B; Stuit L; Mimran A
    J Hypertens; 2004 Feb; 22(2):383-8. PubMed ID: 15076198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic vasopeptidase inhibition restores endothelin-converting enzyme activity and normalizes endothelin levels in salt-induced hypertension.
    Quaschning T; d'Uscio LV; Shaw S; Viswambharan H; Ruschitzka FT; Lüscher TF
    Nephrol Dial Transplant; 2001 Jun; 16(6):1176-82. PubMed ID: 11390717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose enalapril reduces angiotensin II and attenuates diabetic-induced cardiac and autonomic dysfunctions.
    Malfitano C; De Angelis K; Fernandes T; Wichi RB; Rosa K; Pazzine M; Mostarda C; Ronchi FA; Oliveira EM; Casarini DE; Irigoyen MC
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):58-65. PubMed ID: 21921804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker.
    Wang CH; Leung N; Lapointe N; Szeto L; Uffelman KD; Giacca A; Rouleau JL; Lewis GF
    Circulation; 2003 Apr; 107(14):1923-9. PubMed ID: 12668518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo.
    Bäcklund T; Palojoki E; Grönholm T; Eriksson A; Vuolteenaho O; Laine M; Tikkanen I
    Pharmacol Res; 2001 Nov; 44(5):411-8. PubMed ID: 11712872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.
    Dumoulin MJ; Adam A; Rouleau JL; Lamontagne D
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):359-66. PubMed ID: 11300648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left ventricular pressure-volume measurements and myocardial gene expression profile in type 2 diabetic Goto-Kakizaki rats.
    Korkmaz-Icöz S; Lehner A; Li S; Vater A; Radovits T; Brune M; Ruppert M; Sun X; Brlecic P; Zorn M; Karck M; Szabó G
    Am J Physiol Heart Circ Physiol; 2016 Oct; 311(4):H958-H971. PubMed ID: 27521423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic effect of combined treatment with omapatrilat and adrenomedullin on the progression of heart failure in rats.
    Nishikimi T; Mori Y; Ishimura K; Ishikawa Y; Koshikawa S; Akimoto K; Minamino N; Kangawa K; Matsuoka H
    Am J Hypertens; 2006 Oct; 19(10):1039-48. PubMed ID: 17027825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.